Novel antibodies targeting immune regulatory checkpoints for cancer therapy
- 23 July 2013
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 76 (2) , 233-247
Abstract
Cancers must evade or suppress the immune system in order to develop. Better understanding of the molecular regulation governing tumour detection and effective activation of the immune system (so called immune regulatory checkpoints) has provided new targets for cancer immunotherapy. Therapeutic monoclonal antibodies against these targets are currently undergoing clinical evaluation with more in pre‐clinical development; buoyed by the recent licence approval of the anti‐CTLA‐4 antibody, ipilumumab, for use in melanoma. This article will review the current status of the various antibodies and target molecules being investigated.Keywords
This publication has 146 references indexed in Scilit:
- Emerging Tim-3 functions in antimicrobial and tumor immunityTrends in Immunology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Development of autoimmune hepatitis–like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuatorArthritis & Rheumatism, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Anti-CD40 agonist antibodies: Preclinical and clinical experienceUpdate on Cancer Therapeutics, 2007
- Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domainMolecular Immunology, 2007
- BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nature Immunology, 2003
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986